Onkologie. 2009:3(1):19-27

Biological therapy for breast cancer

Luboš Petruželka
Onkologická klinika 1. LF UK a VFN v Praze

The contemporary era of targeted, so-called "patient-tailored", oncological therapy essentially began upon the discovery of hormonal

receptors and targeted clinical use of tamoxifen. Initial clinical use of trastuzumab in combination with chemotherapy in metastatic

breast cancer started the era of bioregulatory nonhormonal therapy for breast cancer (12). Targeted molecular therapy is no longer a

mere subject of research but a reality in the clinical practice of breast cancer treatment.

Keywords: breast cancer, targeted biological therapy, trastuzumab, lapatinib, bevacizumab.

Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petruželka L. Biological therapy for breast cancer. Onkologie. 2009;3(1):19-27.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70. Go to original source... Go to PubMed...
    2. Ramaswamy S, Perou CM. DNA microarrays in breast cancer: the promise of personalised medicine. Lancet 2003; 361: 1576-1577. Go to original source... Go to PubMed...
    3. Sawyers C. Targeted cancer therapy. Nature 2004; 432: 294-297. Go to original source... Go to PubMed...
    4. Petruželka L. Cílená molekulární biologická léčba karcinomu prsu. Referátový výběr z onkologie 2006; speciál 1/06: 33-37.
    5. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-125. Go to original source... Go to PubMed...
    6. Chen XH. Expanding the clinical development of bevacizumab. The Oncologists 2004; 9: 25-34. Go to original source... Go to PubMed...
    7. Pusztai L, Mazouni C, Anderson K, et al. Molecular classification of breast cancer: limitations and potential. Oncologist 2006; 11: 868-877. Go to original source... Go to PubMed...
    8. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398. Go to original source... Go to PubMed...
    9. Petruželka L. Současné možnosti a nové perspektivy systémové léčby karcinomu prsu. Klin Farmakol Farm 2007; 21(3): 11-17.
    10. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003; 8: 335-341. Go to original source... Go to PubMed...
    11. Petruželka L. Hormonální léčba - současný stav a nové možnosti léčby postmenopauzálních žen s hormonálně dependentním karcinomem prsu. Referátový výběr 2007: 15-21.
    12. Slamon DI, Leyland-Jones B, Skah S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 metastatic breast cancer that overexpresses HER-2. N Engl J Med 2001; 344: 783-792. Go to original source... Go to PubMed...
    13. Petruželka L. Karcinom prsu - jak dál v diagnostice a léčbě ve světle nových možností. Vnitř Lék 2007; 53: 22-23.
    14. Miller KD, Wang M, Gralow A, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as firstline therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). SABCS 2005, Program and abstracts; Abst 3. Go to original source...
    15. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus Capecitabine for HER-2-Positive Advanced Breast Cancer NEJM 2007; 355: 2733-2743. Go to original source... Go to PubMed...
    16. Gonzalez-Angulo AM, Hortobagyi GN, Francisco J, et al. Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer, The Oncologist 2006; 11: 857-867. Go to original source... Go to PubMed...
    17. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. Go to original source... Go to PubMed...
    18. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005; 353: 659-672. Go to original source... Go to PubMed...
    19. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-->T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC->TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005; 94(suppl 1): S5. Go to original source...
    20. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820. Go to original source... Go to PubMed...
    21. Goldhirsch A, Wood WC, Gerber RD, et al. Progress and promise: highlights of the international expert konsensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1444. Go to original source... Go to PubMed...
    22. NCCN guidelines version 1/2009.
    23. UpToDate(R) 2009.
    24. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week paclitaxel therapy followed by FAC- Final results of a prospective phase II randomized trial (abstract). Proc Am Soc Clin Oncol 2002; 21: 35abstr.
    25. NCCN Clinical practice guidelines in oncology, Breast Cancer, V/I 2009.
    26. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 3676-3685. Go to original source... Go to PubMed...
    27. Buzdar AU, Valero N, Ibrahim NK, et al. Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clinical Cancer Research 2007; 13: 228-233. Go to original source... Go to PubMed...
    28. Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 552. Go to original source... Go to PubMed...
    29. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/ neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9: 1829.
    30. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10: 2435.
    31. Shepard HM, Lewis GD, Sarup JC, et al. Monoclonal antibody therapy of human cancer: taking the HER-2 protooncogene to the clinic. J Clin Immunol 1991; 11: 117. Go to original source... Go to PubMed...
    32. Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007; 13: 5133. Go to original source... Go to PubMed...
    33. Shattuck DL, Miller JK, Carraway KL, et al. Met receptor contributes to trastuzumab resistance of HER-2-overexpressing breast cancer cells. Cancer Res 2008; 68: 1471. Go to original source... Go to PubMed...
    34. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER-2, a truncated form of the HER-2 receptor, and response to anti-HER-2 therapies in breast cancer. J Natl Cancer Inst 2007; 99: 628. Go to original source... Go to PubMed...
    35. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726. Go to original source... Go to PubMed...
    36. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648. Go to original source... Go to PubMed...
    37. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. New Eng J Med 2001; 34: 783-792. Go to original source... Go to PubMed...
    38. Pegram MD, Konecny GE, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739. Go to original source... Go to PubMed...
    39. Stickeler E, Watermann DO, Woll J, et al. Cardiac safety of pegalated liposomal doxorubicin in combination with trastuzumab in patiens with metastatic breast cancer: results from a multicenter phase II study. J Clin Oncol. 2007; 25: abstr. 1106. Go to original source... Go to PubMed...
    40. Petruželka L. Pegylovaný liposomální doxorubicin, Remedia v tisku.
    41. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 2001; 344: 783-792. Go to original source... Go to PubMed...
    42. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265-4274. Go to original source... Go to PubMed...
    43. Chan A, Petruzelka L, Untch M, et al. Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER-2-positive metastatic breast cancer.
    44. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER-2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007; 110: 965-972. Go to original source... Go to PubMed...
    45. Bontenbal M, Seynaeve C, Stouthard J, et al. Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastzumab/docetaxel as first-line chemotherapy in HER-2-neu positive, metastatic breast cancer (HERTAX study) (Abstract). J Clin Oncol 2008; 26: 44 s. Go to original source... Go to PubMed...
    46. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24: 2786-2792. Go to original source... Go to PubMed...
    47. Pegram M, Forbes J, Pienkowski T, et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER-2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; 25: abstract LBA1008. Go to original source...
    48. Wardley A, Antón-Torres A, Pivot X, et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER-2-positive locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2007; 106: abstract 309.
    49. Mackey J, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER-2-positive metastatic breast cancer. Breast Cancer Res Treat 2006; 100: abstr 3.
    50. Clemens M, Mackey JR, Bapsy P, et al. Trastuzumab plus anastrozole may prolong overall survival in post-menopausal women with HER-2-positive, hormone-dependent metastatic breast cancer: results of a post hoc analysis from the TAnDEM study. In ASCO Breast Cancer Symposium, Edition San Francisco: 2007; abstract 231.
    51. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2neu positive early breast cancer patients (abstract). Data presented at the 29th annual San Antonio Breast Cancer Symposium.
    52. Vukelja S, Rugo H, Vogel C, et al. A phase II study of trastuzumab-DM1, a first-in-class HER-2 antibody-drug conjugate, in patients with HER-2+ metastatic breast cancer. Cancer Res. 2009; 69(suppl 2): 71s. Abstract 33. Go to original source...
    53. Petruželka L, Petruželková L. Lapatinib. Farmakoterapie 2008: 495-507.
    54. Xia W, Liu LH, Ho P, et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004; 23: 646-653. Go to original source... Go to PubMed...
    55. Geyer CE, Martin A, Newstat B, et al. Lapatinib (L) plus capecitabine (C) in HER-2+ advanced breast cancer (ABC): genomic and updated efficacy data. J Clin Oncol. 2007; 25(18S part I). Abstract 1035. Go to original source...
    56. Di Leo A, Gomez H, Aziz Z, et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: a phase III randomized, double-blind study of 580 patients. J Clin Oncol. 2007; 25(18S part I). Abstract 1011. Go to original source...
    57. Burstein HJ, Sun Y, Tan AR, et al. Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER-2+ breast cancer. Cancer Res. 2009; 69(suppl 2): 73s. Abstract 37. Go to original source...
    58. Gelmon KA, Fumleau P, Verma S, et al. Results of a phase II trial of trastuzumab and pertuzumab in patients with HER-2positive metastatic breast cancer who had progressed during trastuzumab therapy. Proc Am Soc Clin Oncol. 2008; 26: 47s. Abstract 1026. Go to original source...
    59. Petruželka L. Jak dál při selhání léčby trastuzumabem u metastazujícího HER-2 dependentního karcinomu prsu. Lékařské Listy 2009; 3: 25-26.
    60. Miller KD, Wang M, Gralow J, et al. Randomized phase III trial of paclitaxel vs. paclitaxel plus bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100) Proc SABCS 2005; abstr 3. Go to original source...
    61. Miles D, Chan A, Romeiu G, et al. Randomized, doubleblind, placebo-controlled phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADO. Proc Am Soc Clin Oncol. 2008; 26(suppl): abstract LBA1011. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.